Ardelyx Inc (ARDX)

Irritable Bowel Syndrome With Constipation (IBS-C) · registered primary completion (date passed, results not yet posted) 2026-09-01 · NCT05643534

Published 2026-09-02Market cap $984M6 sourced statements

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years · PHASE3 · n=180 · active not recruiting

Market

fact

5 approved products already carry Irritable Bowel Syndrome With Constipation (IBS-C) on label, including Lubiprostone, Linzess, LUBIPROSTONE, Amitiza. Approval would enter an occupied market.

Source: FDA label index

Trial registry

fact

Registered design for NCT05643534: randomized, double-masked, 180 participants (actual). Primary outcome: 6/12-week APS (abdominal pain and SBM) +2 response.

Source: ClinicalTrials.gov record

Runway

fact

Cash of $282M against operating outflow of $14M per quarter gives roughly 20.5 quarters of runway.

Source: 10-Q filed 2026-08-06

Share count and dilution

fact

249,187,572 shares outstanding against 294,807,572 if every outstanding option, warrant and convertible were exercised. In that case 15.5% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-06

Pipeline

fact

2 distinct molecules in 3 active company-sponsored trials; Tenapanor 5 mg BID accounts for 4 of them at Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 5.3%.

Source: DEF 14A filed 2026-04-29

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.